CELESTE MCGLAMERY: Open Payments
NPI 1326574138 · OLATHE, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$941 in 62 payments from 12 companies in 2025. Trend: 2023 $754 · 2024 $754 · 2025 $941
Food & beverage: $941
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $366 |
| Lilly USA, LLC | 4 | $115 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $103 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Madrigal Pharmaceuticals | 3 | $61 |
| PFIZER INC. | 3 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Janssen Biotech, Inc. | 2 | $40 |
| Intercept Pharmaceuticals, Inc. | 2 | $35 |
| GENZYME CORPORATION | 1 | $19 |
Products named: SKYRIZI, OMVOH, XIFAXAN, DUPIXENT, REZDIFFRA, RINVOQ, TERLIVAZ, LINZESS.
Industry payments across KS — which companies pay providers there.
